Retatrutide vs semaglutide weight loss is one of the most searched GLP-class comparisons in 2026. Phase 2 clinical trial data shows retatrutide produces ~24% average weight loss versus ~15% for semaglutide (Wegovy) — a ~9 percentage point difference driven by retatrutide's triple receptor mechanism. This guide breaks down the head-to-head data, timelines, side effects, and which is better for different research profiles.
The difference in average weight loss between retatrutide and semaglutide comes down to receptor mechanism. Semaglutide is a pure GLP-1 receptor agonist — it activates a single receptor pathway that suppresses appetite, slows gastric emptying, and improves insulin secretion. This single mechanism produces ~15% weight loss at maximum dose.
Retatrutide is a triple agonist: it activates GLP-1 receptors (appetite suppression), GIP receptors (which enhance GLP-1 effects and may reduce GI side effects), and glucagon receptors (which increase energy expenditure and fat oxidation). This triple mechanism works through three complementary pathways simultaneously — the glucagon receptor component is the key differentiator, as it increases basal metabolic rate and fat oxidation in addition to reducing caloric intake.
The divergence in weight loss results between retatrutide and semaglutide becomes most pronounced after week 24, when both compounds approach their maintenance doses. Early results (weeks 4–12) are comparable because both start at low titration doses. The glucagon receptor component of retatrutide becomes increasingly active at higher doses, driving the accelerating divergence in average weight loss after week 24.
| Timepoint | Semaglutide | Retatrutide |
|---|---|---|
| Week 4 | ~2–3% | ~2–3% |
| Week 12 | ~5–7% | ~6–8% |
| Week 24 | ~9–11% | ~13–16% |
| Week 36 | ~12–14% | ~19–21% |
| Week 48 | ~14–16% | ~22–24% |
| Week 68 | ~15–17% | N/A (Phase 3 ongoing) |
Semaglutide data from STEP-1 trial (Wegovy 2.4 mg). Retatrutide data from Phase 2 TRIUMPH trial (24 mg). Direct head-to-head clinical trial data is not yet available. Individual responses vary.
| Parameter | Semaglutide | Retatrutide |
|---|---|---|
| Receptor mechanism | GLP-1 mono-agonist | GLP-1 + GIP + Glucagon (triple) |
| Average weight loss (max dose) | ~15% (Wegovy 2.4 mg, STEP-1) | ~24% (24 mg, Phase 2) |
| Average weight loss (mid dose) | ~10–14% (Ozempic 1–2 mg) | ~17% (12 mg, Phase 2) |
| Titration period | 16–20 weeks | ~24 weeks |
| Nausea rate (therapeutic dose) | 30–44% | 47–58% |
| GI discontinuation rate | ~5–8% | ~8–12% |
| Half-life | ~7 days (weekly injection) | ~6 days (weekly injection) |
| FDA approval status | Approved (Ozempic/Wegovy) | Phase 3 trials (est. 2027–2028) |
| Cardiovascular outcome data | SELECT trial (20% CV risk ↓) | Not yet available |
| Long-term safety data | 5+ years real-world data | Phase 2 data only (48 weeks) |
| Blood sugar control | Strong (T2D approved) | Strong (Phase 2 data) |
| Research-grade availability | Available (Purgo Labs) | Available (Purgo Labs) |
Yes — significantly more. Retatrutide produced ~24% mean body weight reduction at 48 weeks in Phase 2 TRIUMPH trials (24 mg dose), compared to semaglutide's ~15% (Wegovy 2.4 mg, STEP-1 trial at 68 weeks). This ~9 percentage point difference translates to roughly 6–9 additional kg of weight loss for a 90 kg individual. The difference is driven by retatrutide's triple agonism (GLP-1 + GIP + glucagon receptor), which adds glucagon-mediated energy expenditure on top of GLP-1/GIP appetite suppression.
Retatrutide vs Ozempic is not a direct head-to-head comparison in clinical trials, but the data is clear: Ozempic (semaglutide 1.0–2.0 mg) produces ~10–14% weight loss in SUSTAIN trials, while retatrutide (24 mg) produced ~24% in Phase 2. Even at lower doses, retatrutide (12 mg) produced ~17% weight loss — comparable to Wegovy at its maximum dose. For weight loss specifically, retatrutide is the more potent active ingredient.
For average weight loss, yes — retatrutide outperforms Wegovy (semaglutide 2.4 mg) in Phase 2 data: ~24% vs ~15% body weight reduction. However, Wegovy has a significant advantage in clinical evidence depth: it has completed multiple Phase 3 trials, has FDA approval, and has 5+ years of real-world safety data. Retatrutide is still in Phase 3 trials (TRIUMPH program) with estimated FDA approval in 2027–2028. For researchers evaluating long-term safety data, semaglutide currently has a more complete evidence base.
Semaglutide is a pure GLP-1 receptor agonist — it activates only the GLP-1 receptor, producing appetite suppression, slowed gastric emptying, and improved insulin secretion. Retatrutide is a triple agonist: it activates GLP-1 receptors (appetite suppression), GIP receptors (which may enhance GLP-1 effects and reduce GI side effects), and glucagon receptors (which increase energy expenditure and fat oxidation). This triple mechanism is why retatrutide produces greater average weight loss — it works through three complementary pathways simultaneously.
Both compounds share the same GLP-1 class common side effects: nausea, vomiting, diarrhea, and constipation. Retatrutide has a higher nausea rate (~47–58% at therapeutic doses vs ~30–44% for semaglutide) due to its greater potency and triple agonism. GI discontinuation rates are also slightly higher for retatrutide (~8–12% vs ~5–8%). Both require slow titration protocols to manage GI tolerance. Long-term safety data for retatrutide is more limited than semaglutide, which has 5+ years of real-world use.
Both compounds show meaningful weight loss within 4–8 weeks of reaching therapeutic doses. Semaglutide reaches maintenance dose (~2.4 mg Wegovy) after 16–20 weeks of titration, with most weight loss occurring over 52–68 weeks. Retatrutide reaches its maximum studied dose (24 mg) after approximately 24 weeks of titration, with Phase 2 data showing ~24% weight loss at 48 weeks. The titration period for retatrutide is longer due to its higher potency and the need for careful GI tolerance development.
Prescription semaglutide (Wegovy/Ozempic) costs $800–$1,400/month without insurance in the US. Retatrutide is not yet FDA-approved and is not commercially available as a prescription drug. Research-grade semaglutide and retatrutide are available from vendors like Purgo Labs for research purposes at significantly lower cost than pharmaceutical versions. Pricing for research-grade compounds varies by vendor and batch size.
Purgo Labs provides pharmaceutical-grade retatrutide and semaglutide with third-party COAs confirming ≥99% purity. Both compounds are available for research use with independent batch testing — the standard required for meaningful weight loss research. Use code HEALTH for 15% off your first order.
Shop Purgo LabsUse code HEALTH for 15% off · Research use only
Medical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.